Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation (Q51735777)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 May 2014

Language	Label	Description	Also known as
English	Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation	scientific article published on 12 May 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

1 reference

based on heuristic

inferred from title

author name string

J Tischer

1

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

N Engel

2

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

S Fritsch

3

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

D Prevalsek

4

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

M Hubmann

5

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

C Schulz

6

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

A K Zoellner

7

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

V Bücklein

8

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

S Lippl

9

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

R Reibke

10

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

C T Rieger

11

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

G Ledderose

12

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

H J Stemmler

13

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

W Hiddemann

14

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

C Schmid

15

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

A Hausmann

16

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

language of work or name

0 references

publication date

12 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

49

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

7

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

895-901

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG /- Ida) and second allogeneic stem cell transplant.

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000).

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

A retrospective review of the outcome after second or subsequent allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Infectious complications after allogeneic stem cell transplantation: incidence in matched-related and matched-unrelated transplant settings

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Modern Therapy of Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038/BMT.2014.83

21 January 2018

Second allografts for relapsed hematologic malignancies: feasibility of using a different donor

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Increased susceptibility to fungal infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft failure after allogeneic transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second HLA-identical sibling transplants for leukemia recurrence

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second bone marrow transplantation for leukemia in untreated relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second allogeneic hematopoietic stem cell transplantation for leukemia relapse after first allogeneic transplantation: outcome of 16 patients in a single institution

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1994 Consensus Conference on Acute GVHD Grading

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24820212

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BMT.2014.83

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24820212

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51735777&oldid=2281621596"